Skip to Content

Notice

Bulk Manufacturer of Controlled Substances Application: Sigma Aldrich Research

This document has a comment period that ends in 47 days. (08/12/2019) Submit a formal comment

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

ACTION:

Notice of application.

DATES:

Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 12, 2019.

ADDRESSES:

Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

In accordance with 21 CFR 1301.33(a), this is notice that on March 7, 2019, Sigma Aldrich Research, Biochemicals, Inc., 400-600 Summit Drive, Burlington, Massachusetts 01803 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substanceDrug codeSchedule
Cathinone1235I
Mephedrone (4-Methyl-N-methylcathinone)1248I
Lysergic acid diethylamide7315I
Tetrahydrocannabinols7370I
3,4-Methylenedioxymethamphetamine7405I
Alpha-methyltryptamine7432I
Dimethyltryptamine7435I
5-Methoxy-N,N-diisopropyltryptamine7439I
N-Benzylpiperazine7493I
2-(2,5-Dimethoxyphenyl) ethanamine (2C-H)7517I
MDPV (3,4-Methylenedioxypyrovalerone)7535I
Methylone (3,4-Methylenedioxy-N-methylcathinone)7540I
Heroin9200I
Normorphine9313I
Norlevorphanol9634I
Amphetamine1100II
Nabilone7379II
Phencyclidine7471II
Cocaine9041II
Codeine9050II
Ecgonine9180II
Levorphanol9220II
Meperidine9230II
Methadone9250II
Morphine9300II
Thebaine9333II
Levo-alphacetylmethadol9648II
Noroxymorphone9668II
Remifentanil9739II
Sufentanil9740II
Carfentanil9743II
Fentanyl9801II

The company plans to manufacture reference standards.

Start Signature

Dated: June 3, 2019.

John J. Martin,

Assistant Administrator.

End Signature End Supplemental Information

[FR Doc. 2019-12503 Filed 6-12-19; 8:45 am]

BILLING CODE 4410-09-P